The most common grade @ or more adverse events were hypertension ( @ -LSB- @ % -RSB- of @ patients receiving bevacizumab plus chemotherapy vs @ -LSB- @ % -RSB- of @ patients receiving chemotherapy alone ) , neutropenia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , and hand-foot syndrome ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) .